Acylin Therapeutics

United States
Seattle, United States, Washington

Company profile

Acylin Therapeutics company profile

Acylin Therapeutics is the first company focused on developing inhibitors of cellular acetylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation as a cellular signal transduction regulator potentially as ubiquitous and important as phosphorylation by kinase enzymes. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding. Acylin has prioritized the p300 and CBP histone acetyl transferases [HATs] for initial drug discovery.

Business identity

Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Founded
2009-01-01

Headquarters

Headquarters
Seattle, United States, Washington
Postal code
98102
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$6.4M
Last funding
Series A / $2M / 2012-06-04
Last equity funding
Series A / $2M
Investors
4
Founders
1
Articles
1

Founders and investors

Founders

Suresh Jain

Investors

Alexandria Real Estate EquitiesAmgen VenturesARCH Venture PartnersOVP Venture Partners

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.